Nanopublications

Matches in Nanopublications for { ?s ?p "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." ?g. }

Showing items 1 to 100 of ±156 with 100 items per page.

SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.